A once-a-day drug has been approved by the Food and Drug Administration (FDA) for the treatment of adults with ADHD (Attention Deficit Hyperactivity Disorder). The FDA, similar to the Romanian National Medicines Agency, initially approved Qelbree in 2021 for the treatment of ADHD in children between the ages of 6 and 17. Qelbree is the first non-stimulant drug approved to treat ADHD in adults in 20 years, Medical News Today reports.
People with ADHD take the medicine once a day and it is available in a prolonged-release capsule.
–
ADHD leads to depression and anxiety
ADHD is a neuro-behavioral disorder that can cause hyperactivity and inattention. The symptoms of the disorder are often present during childhood and can continue into adulthood.
When ADHD is left untreated in adults, it can cause relationship difficulties, job instability, and mental health problems, such as depression and anxiety. Fortunately, there are a number of treatment options for ADHD.
“Similar to the latest FDA-approved non-stimulant for ADHD called atomoxetine, the mechanism of viloxazine also involves an increase in a brain neurotransmitter called norepinephrine that we know is important for attention,” said Dr. David Merrill.
According to the results of the clinical study published by the manufacturer, participants who took Qelbree had a 41% decrease in symptoms, while people who took a placebo had a 32% reduction in symptoms.
Appears in childhood
ADHD is the most common neurodevelopmental disorder in childhood. The disease is commonly diagnosed in children around the age of 6-7 years and often continues into adolescence and adulthood.
Children with ADHD may have difficulty maintaining attention, controlling behaviors, or may be overactive. Most often, the child has all three components of this disorder, namely inattention, impulsivity, hyperactivity, in a variable combination of severity.
ADHD symptoms in adults may not be as clear as in children. In adults, hyperactivity may decrease, but impulsivity, inability to sit still, and difficulty concentrating may still be present.
–
